IFITM2 Antikörper (AA 1-100)

Produktnummer ABIN7267949

Produktdetails anti-IFITM2 Antikörper

Target: IFITM2 (Interferon Induced Transmembrane Protein 2 (IFITM2))

Bindungsspezifität: AA 1-100

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IFITM2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Verwendungszweck: IFITM2 Rabbit pAb

Sequenz: MNHIVQTFSP VNSGQPPNYE MLKEEQEVAM LGVPHNPAPP MSTVIHIRSE TSVPDHVVWS LFNTLFMNTC CLGFIAFAYS VKSRDRKMVG DVTGAQAYAS

Kreuzreaktivität: Human

Produktmerkmale: Polyclonal Antibodies

Aufreinigung: Affinity purification

Immunogen: A synthetic peptide corresponding to a sequence within amino acids 1-100 of human IFITM2 (NP_006426.2).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB,1:500 - 1:2000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu IFITM2

Target: IFITM2 (Interferon Induced Transmembrane Protein 2 (IFITM2))

Andere Bezeichnung: IFITM2 (IFITM2 Produkte)

Synonyme: 1-8D antikoerper, DSPA2c antikoerper, Ifitm3l antikoerper, fragilis3 antikoerper, mil-3 antikoerper, Ifitml antikoerper, interferon induced transmembrane protein 2 antikoerper, IFITM2 antikoerper, Ifitm2 antikoerper

Hintergrund: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1, hepatitis C virus (HCV and vesicular stomatitis virus (VSV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM2,1-8D,DSPA2c,Cancer,Tumor immunology,Tumor-associated antigens,Immunology & Inflammation,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,IFITM2

Molekulargewicht: 14kDa

Gen-ID: 10581

UniProt: Q01629